25 Years of progress in the treatment of retinal diseases: Where we have been, where we are now, and where we will be

Retina

Volumn 26, Issue 6 SUPPL., 2006, Pages

  Bhavsar, Abdhish R ^a,c   Tornambe, Paul E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Retina Consultants   (United States)

^c Retina Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; DEXTRAN; FIBRINOLYTIC AGENT; FLUOCINOLONE; HYALURONIDASE; PEGAPTANIB; PLASMIN; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; SOMATOSTATIN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BODY POSTURE; CHOROID MELANOMA; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; ENUCLEATION; GENE TRANSFER; HEMODILUTION; HUMAN; LASER COAGULATION; MEDICAL PRACTICE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINOBLASTOMA; RISK REDUCTION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; EDITORIAL; OPHTHALMOLOGY; TREATMENT OUTCOME;

HUMANS; OPHTHALMOLOGY; RETINAL DISEASES; TREATMENT OUTCOME;

EID: 33747188100     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000236450.70275.6d     Document Type: Conference Paper

References (35)

1. Nietzsche F. The Columbia Encyclopedia, 6th ed. New York: Columbia University Press, 2001-04. Available at: www. bartleby.com/65/. Accessed September 11, 2005.
2. Kelly N. Personal communication, July 2005.
3. Senile Macular Degeneration Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-918.
4. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990;108:816-824.
5. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-1257.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-1345.
7. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial GroupPegaptanib for neovascular agerelated macular degeneration. N Engl J Med 2004;351:2805-2816.
8. Heier JS, Focus Study Group. Intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy for neovascular age-related macular degeneration: year one results. Presented at the annual meeting of the American Society of Retina Specialists; July 18, 2005; Montreal, Canada.
9. Miller JW, Chung CY, Kim RY, MARINA Study Group. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Presented at the annual meeting of the American Society of Retina Specialists; July 18, 2005; Montreal, Canada.
10. Hawkins BS, Bressler NM, Miskala PH, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004;111:1967-1980.
11. Bressler NM, Bressler SB, Childs AL, et al. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004;111:1993-2006.
12. Gonin J. The treatment of detached retina by searing the retinal tears. Arch Ophthalmol 1930;4:621-623.
13. Shields JA, Giblin ME, Shields CL, et al. Episcleral plaque radiotherapy for retinoblastoma. Ophthalmology 1989;96:530-537.
14. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol 1978;62:420-425.
15. Manschot WA, Van Peperzeel HA. Choroidal melanoma: enucleation or observation? A new approach. Arch Ophthalmol 1980;98:71-77.
16. Abramson DH. Second nonocular cancers in retinoblastoma: a unified hypothesis. The Franceschetti Lecture. Ophthalmic Genet 1999;20:193-204.
17. Shields CL, DePotter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-1338.
18. Murphree AL, Villablanca JG, Deegan WF III, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-1356.
19. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of iodine-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS report no. 18. Arch Ophthalmol 2001;119:969-982.
20. Pavan PR, Brinser JH. Exogenous bacterial endophthalmitis treated without systemic antibiotics. Am J Ophthalmol 1987;104:121-126.
21. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
22. Singh S, Josephberg RJ, Zaidman GW. Office-based diagnostic pars plana vitrectomy. Invest Ophthalmol Vis Sci 1996;37:402.
23. Hilton GF, Josephberg RG, Halperin LS. Office-based sutureless transconjunctival pars plana vitrectomy. Retina 2002;22:725-732.
24. Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica 2003;217:167-188.
25. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2006 (in press).
26. The Diabetic Retinopathy Study Research Group. Preliminary report on the effect of photocoagulation therapy. Am J Ophthalmol 1976;81:383-396.
27. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
28. The Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
29. DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
30. The UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853.
31. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
32. Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol 1985;103:1796-1806.
33. Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9. Ophthalmology 1991;98:766-785.
34. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report #2. Arch Ophthalmol 1985;103:1644-1652.
35. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report #3. Ophthalmology 1988;95:1307-1320.